KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Inventory (2016 - 2025)

Historic Inventory for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $11.5 billion.

  • Pfizer's Inventory fell 215.85% to $11.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 billion, marking a year-over-year decrease of 215.85%. This contributed to the annual value of $10.9 billion for FY2024, which is 649.72% up from last year.
  • Per Pfizer's latest filing, its Inventory stood at $11.5 billion for Q3 2025, which was down 215.85% from $11.7 billion recorded in Q2 2025.
  • Pfizer's 5-year Inventory high stood at $11.7 billion for Q3 2024, and its period low was $8.5 billion during Q2 2021.
  • Over the past 5 years, Pfizer's median Inventory value was $10.2 billion (recorded in 2023), while the average stood at $10.2 billion.
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 704.68% in 2021, then skyrocketed by 1749.68% in 2022.
  • Over the past 5 years, Pfizer's Inventory (Quarter) stood at $9.1 billion in 2021, then dropped by 0.86% to $9.0 billion in 2022, then rose by 13.45% to $10.2 billion in 2023, then increased by 6.5% to $10.9 billion in 2024, then increased by 5.69% to $11.5 billion in 2025.
  • Its Inventory stands at $11.5 billion for Q3 2025, versus $11.7 billion for Q2 2025 and $10.9 billion for Q1 2025.